No Data
Nanobiotix Strengthens Growth and Financial Prospects
Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves
Press Release: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
NANOBIOTIX to Participate in Multiple Investor Conferences in November
Nanobiotix Updates Voting Rights and Capital Shares
Express News | Nanobiotix SA : Jefferies Cuts Target Price to $10.6 From $11
No Data
No Data